Sanctura Related Published Studies
Well-designed clinical trials related to Sanctura (Trospium)
Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. [2008.03]
Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. [2007.09]
Once Daily Trospium Chloride is Effective and Well Tolerated for the Treatment of Overactive Bladder: Results From a Multicenter Phase III Trial. [2007.07.13]
Trospium chloride in patients with neurogenic detrusor overactivity: is dose titration of benefit to the patients? [2006.12]
Multicenter phase III trial studying trospium chloride in patients with overactive bladder. [2006.02]
Trospium chloride for the treatment of overactive bladder with urge incontinence. [2005.05]
Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder. [2004.12]
Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. [2004.06]
Trospium chloride for the treatment of detrusor instability in children. [2003.11]
Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. [2003.05]
Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. [2001.06]
Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomized, double-blind, multicentre clinical trial. [2000.04]
Bioavailability of trospium chloride after intravesical instillation in patients with neurogenic lower urinary tract dysfunction: A pilot study. [1999]
Effects of two anticholinergic drugs, trospium chloride and biperiden, on motility and evoked potentials of the oesophagus. [1998.10]
[Intravesical instillation of trospium chloride, oxybutynin and verapamil for relaxation of the bladder detrusor muscle. A placebo controlled, randomized clinical test] [1998.05]
Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia. [1995.04]
Effect of the quaternary ammonium compound trospium chloride on 24 hour jejunal motility in healthy subjects. [1994.01]
Safety and tolerance of trospium chloride in the high dose range. [1993.04]
The effect of trospium chloride on oesophageal motility. [1993.02]
Ultrasound studies of the effect of trospium chloride on gall-bladder kinetics. [1992.12]
Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries. A multicentre placebo-controlled double-blind trial. [1991]
Well-designed clinical trials possibly related to Sanctura (Trospium)
Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. [2008.05]
Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. [2006.03]
The overactive bladder-symptom composite score: a composite symptom score of toilet voids, urgency severity and urge urinary incontinence in patients with overactive bladder. [2005.05]
Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged > or = 50 years. [2005.02]
Other research related to Sanctura (Trospium)
Role of trospium chloride in brachytherapy-related detrusor overactivity. [2008.03]
Comparison of the efficacy and tolerability of solifenacin succinate with or without previous use of trospium chloride. [2007.09]
Trospium chloride: Distinct among other anticholinergic agents available for the treatment of overactive bladder. [2006.11]
Predictive power of an in vitro system to assess drug interactions of an antimuscarinic medication: a comparison of in vitro and in vivo drug-drug interaction studies of trospium chloride with digoxin. [2006.07]
Intravesical instillation of human urine after oral administration of trospium, tolterodine and oxybutynin in a rat model of detrusor overactivity. [2006.02]
Trospium chloride: an anticholinergic quaternary ammonium compound for the treatment of overactive bladder. [2005.07]
Clinical pharmacokinetics of trospium chloride. [2005]
Absorption pattern of trospium chloride along the human gastrointestinal tract assessed using local enteral administration. [2004.10]
Preview of new drugs for overactive bladder and incontinence: darifenacin, solifenacin, trospium, and duloxetine. [2004.10]
Trospium chloride in the management of overactive bladder. [2004]
Trospium chloride in patients with detrusor overactivity: meta-analysis of placebo-controlled, randomized, double-blind, multi-center clinical trials on the efficacy and safety of 20 mg trospium chloride twice daily. [2002.07]
Trospium chloride--an effective drug in the treatment of overactive bladder and detrusor hyperreflexia. [2001.11]
[Clinical trial to evaluate trospium chloride (Uraplex) effectiveness and tolerance in patients with detrusor instability incontinence and its impact on quality of life] [2000.03]
Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. [1994]
Effect of trospium chloride on gastrointestinal motility in humans. [1993]
[High-dose trospium chloride in therapy of detrusor hyperreflexia] [1991.07]
Other possibly related research studies
Role of muscarinic receptor antagonists in urgency and nocturia. [2005.09]
A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. [2005.08]
Contemporary and emerging drug treatments for urinary incontinence in children. [2005]
Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. [2005.02]
[Urinary incontinence: anticholinergic treatment] [2004.10]
Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways. [2005.02]
[Medical therapy of urinary incontinence] [2005.01]
Elevating our therapeutic expectations in overactive bladder. [2004.10]
Painful sweating. [2004.10.26]
Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations. [2004]
Clinical pharmacokinetics of drugs used to treat urge incontinence. [2003]
Update on overactive bladder: pharmacologic approaches on the horizon. [2003.10]
[New pharmacological treatment concepts for overactive bladder] [2003.06]
Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. [2002]
Advancements in pharmacologic management of the overactive bladder. [2000.12.04]
Responses of isolated normal human detrusor muscle to various spasmolytic drugs commonly used in the treatment of the overactive bladder. [2000.05]
Importance of pharmacological and physicochemical properties for tolerance of antimuscarinic drugs in the treatment of detrusor instability and detrusor hyperreflexia--chances for improvement of therapy. [1999.05]
[Medical treatment of bladder instability. Our experience] [1997.07]
[Bladder dysfunctions in encephalomyelitis disseminata--drug and interventional therapeutic options] [1995.12]
Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. [2006.10.18]
Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. [2006]
Practical considerations of new drugs: new choices for old problems. [2006.04]
Management of overactive bladder and urge urinary incontinence in the elderly patient. [2006.03]
Using anticholinergics to treat overactive bladder: the issue of treatment tolerability. [2006.03]
Overactive bladder in the elderly: a guide to pharmacological management. [2005]
The Q-T interval and antimuscarinic drugs. [2005.11]
Improving the tolerability of anticholinergic agents in the treatment of overactive bladder. [2005]
Newer agents for the management of overactive bladder. [2006.12.15]
Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder. [2006.12]
[Oral anticholinergics in overactive bladder] [2006.07]
Efficacy, tolerability and safety of propiverine hydrochloride in children and adolescents with congenital or traumatic neurogenic detrusor overactivity--a retrospective study. [2006.06]
Muscarinic receptors in the bladder: from basic research to therapeutics. [2006.02]
[Intravesical treatment of overactive bladder syndrome] [2006.10]
Overactive bladder treatments in early phase clinical trials. [2007.07]
Treatment of overactive bladder: selective use of anticholinergic agents with low drug-drug interaction potential. [2007.05]
Maximizing anticholinergic therapy for overactive bladder: has the ceiling been reached? [2007.06]
Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites? [2006.11]
[How do medications used to treat urinary incontinence affect the cerebral function of the elderly?] [2007.04]
Muscarinic receptor antagonists for overactive bladder. [2007.11]
Pharmacologic management of overactive bladder. [2007]
Urgency in overactive bladder: Translating experimental data into clinical practice. [2008.05]
[Anticholinergic drugs in overactive bladder] [2008.01]
The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. [2008.09]
Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. [2008.04]
Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. [2008.08.11]
|
